April 2025 - Page 2 of 2 - BioMedWire (BMW)

ThursdayApr 03, 2025 10:00 am

Study Suggests Possible Link Between ADHD and Heightened Dementia Risk

ADHD, or attention deficit hyperactivity disorder, is usually diagnosed during one’s childhood, but more adults are being diagnosed with this condition. Experts have observed that among adults diagnosed with ADHD, the likelihood of developing dementia is heightened, but it hasn’t been clear why this is the case. Now a new study suggests a possible explanation for the increased possibility of dementia development among adult ADHD sufferers. A press release issued by Prof. Paul Unschuld, who initiated this study, indicates that while epidemiological studies indicated a heightened risk of dementia development among adults diagnosed with ADHD, the mechanisms behind this link…

ThursdayApr 03, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment

Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026. SNGX’s HyBryte is a novel photodynamic therapy using synthetic hypericin activated by safe visible light. The ongoing phase 3 replication study meets stringent requirements of regulatory agencies to strengthen the case for HyBryte as a commercially available treatment. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and unmet medical needs, is making significant strides in its efforts to bring innovative therapies to patients with early-stage cutaneous T-cell lymphoma (“CTCL”). The company’s lead candidate,…

WednesdayApr 02, 2025 9:45 am

Clene Inc. (NASDAQ: CLNN) to Share CNM-Au8(R) Progress at Jones Las Vegas Conference

The company will present at the Jones Las Vegas Technology and Innovation Conference on April 8-9, to update investors on its lead drug candidate. The conference will provide one-on-one meetings and networking opportunities for institutional investors and executives. Clene recently received FDA guidance on a potential accelerated approval pathway for CNM-Au8 in ALS treatment. New analyses suggest CNM-Au8 improves survival for ALS patients, with a 4.1-month increase in restricted mean survival time. Clene plans to begin enrollment for a Phase 3 confirmatory trial (RESTORE-ALS) in mid-2025. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical…

TuesdayApr 01, 2025 10:00 am

Study Explains Why Melanoma, Other Cancers Evade and Resist Immunotherapy

Cutaneous melanoma is the most aggressive skin cancer type and it is characterized by manifesting diverse mutations. Under normal circumstances, several of these mutations could be identified as threats by the immune system, but in this type of cancer, this doesn’t happen. Consequently, most patients are unresponsive to immunotherapy. This challenge has baffled oncology researchers for years. Now new research conducted by CNIO Melanoma Group located at the National Cancer Research Center in Spain has discovered the mechanism through which aggressive tumors like cutaneous melanoma evade the immune system in a way that isn’t expected. The study team, headed by…